Navigation Links
Jazz Pharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
Date:5/7/2009

p>

Research and development expenses for the first quarter of 2009 were $11.4 million, compared to $21.2 million for the first quarter of 2008. Reduced expenses in the first quarter of 2009 reflect Jazz Pharmaceuticals' decision that its JZP-4, JZP7, and JZP-8 programs will continue to the next phase of development only upon partnering or other funding for the programs.

Selling, general and administrative expenses for the first quarter of 2009 were $14.2 million, compared to $32.8 million for the first quarter of 2008. The decrease in the first quarter of 2009 reflects a decrease in spending on Luvox CR and the 2008 reductions in force.

Jazz Pharmaceuticals' net loss for the first quarter of 2009 was $13.0 million, compared to a net loss of $46.7 million for the first quarter of 2008.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information see www.JazzPharmaceuticals.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, statements related to future product sales, the results of the second pivotal trial for JZP-6 and the timing thereof, the planned submission of an NDA and the timing thereof, and potential partnering arrangements for certain of the company's programs. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
2. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
4. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
7. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
8. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
9. Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
10. Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)... Ennis, P.A. is offering free nationwide confident...h control pills who have suffered a Deep Vein Thro...tack or other related cardiac issues or had their ...-800-856-6405 or go to the firm’s website at...case evaluation form. , (...
(Date:11/25/2009)...5 The Bartle Hall Convention Cente...ical clinic on Dec. 9-10, when Kansas City hosts t...uninsured people. ,, "This free clinic event ha... it will extend over two days instead of just one ..." Sheri Wood, executive director of the Kansas Cit...
(Date:11/25/2009).... 25 /PRNewswire/ - Sentinelle Medical Inc., a lea...RI) coils and software and Calgary Scientific Inc....gies, have introduced a web version of Aegis(TM) B...is innovative interface is the first truly zero-fo...in the market. Calgary Scientific,s PureWeb(TM) pl...
(Date:11/25/2009)...25 Thanksgiving meals will be deli...the greater Long Beach area thanks to Faith In Act... by Independence at Home (IAH), a division of SCAN...ations have gathered hundreds of volunteers to del... Long Beach, Lakewood, Signal Hill, South Bay, Sou...
(Date:11/25/2009)...RNewswire-USNewswire/ -- The Black AIDS Institute ...mine executive leadership for 2010. ,, The new ...s with specialties in public policy, law, finance,...ss entrepreneurship. The Board also comes from a w...eterosexual and gay Black men and women, some livi...
Breaking Medicine News(10 mins):Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3Health News:SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors 2Health News:Black AIDS Institute Announces 2010 Board Election Results 2
...Medical Technologies, Inc. (Nasdaq: VNUS ), a lea... invasive treatment of peripheral vascular,disease...ncial results for,the first quarter ended March 31...his call will be webcast live for all,investors an...
...pplications in humans, researchers say , ... neurons derived from reprogrammed adult skin cell... mice and reduced symptoms of a Parkinson,s diseas...or positively affect neurodegenerative disease," s...
...re testimonial by client and i..., 2008 Leventhal Weight Loss,Incorporated, http:...tion executive,weight loss consulting service for ...y a client who has lost twenty,pounds, and an inte...
...top beauty and wellness corporations c...7, 2008 5W Public Relations will host,the 2008 Bo...rence for,media and industry insiders in the beaut...ril 22nd, brands including Clarins, Physicians For...
...nc.,(Nasdaq: ENMD ), a clinical-stage pharmaceuti...ent of cancer and inflammatory diseases, today,ann...Director, effective,June 5, 2008., (Logo: http:/...pany chart its path forward in,multi-mechanism onc...
...es,Inc. (NYSE: FRX ), an international manufactur...elease its Fiscal 2008 Fourth Quarter,financial re...y, April 15,2008. Later that day, at 10:00 AM EDT,...f Financial Officer, will discuss the,financial re...
Other Medicine News:Health News:VNUS Medical Technologies to Report First-Quarter 2008 Results and Webcast Teleconference on April 21 2Health News:Reprogrammed Cells Reduce Parkinson's Symptoms 2Health News:Attorney Weight Loss Video to be Released by Leventhal Weight Loss Incorporated 2Health News:5W Public Relations Presents the 2008 Body Beautiful Media Symposium Benefiting The Skin Cancer Foundation 2Health News:5W Public Relations Presents the 2008 Body Beautiful Media Symposium Benefiting The Skin Cancer Foundation 3Health News:Dr. Ronald E. Cape to Retire from EntreMed Board of Directors 2Health News:Dr. Ronald E. Cape to Retire from EntreMed Board of Directors 3Health News:Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Fourth Quarter Earnings 2
(Date:11/25/2009)..., FRAMINGHAM, Mass. and SYDNEY, Nov. 25 /PRNewsw...asdaq: HTWR ; ASX: HIN), a leading innovator and ...y support technologies revolutionizing the treatme... it is scheduled to make an investor presentation ...rence at 8:00 am EST on Wednesday, December 2, 200...
(Date:11/24/2009)..., PITTSBURGH, Nov. 24 ,, WHAT... in coma for 23 years following an auto accident, ... time and was the subject of a Good Morning Americ... segment to illustrate how people with Locked-in S...ion. ,, WHEN: Good Morning America -- Tuesday...
(Date:11/24/2009)..., FREMONT, Calif., Nov. 24 /PRNewswire-FirstCall/ ...nounced the Company filed its Plan of Reorganizati...09, with the United States Bankruptcy Court for th...oval of the Disclosure Statement is presently sche...e confirmation of the Plan scheduled for January 7...
Breaking Medicine Technology:HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City 2DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Vermillion Files Plan of Reorganization 2Vermillion Files Plan of Reorganization 3Vermillion Files Plan of Reorganization 4LCA Vision Announces CEO Resignation 14140 1LCA Vision Announces CEO Resignation 14140 2HLTH Corporation Announces Agreement to Sell Porex Unit to Aurora Capital Group for 24142 Million 57623 1HLTH Corporation Announces Agreement to Sell Porex Unit to Aurora Capital Group for 24142 Million 57623 2HLTH Corporation Announces Agreement to Sell Porex Unit to Aurora Capital Group for 24142 Million 57623 3Long Term Care Seminars in Dayton Cleveland Cincinnati and Columbus Free to Public 57619 1Long Term Care Seminars in Dayton Cleveland Cincinnati and Columbus Free to Public 57619 2Long Term Care Seminars in Dayton Cleveland Cincinnati and Columbus Free to Public 57619 3
...Model Created Using Piecewise Smooth Subdivision S...ation of Tetralogy of Fallot Patients, SEATTLE, A...he right ventricle provides important shape and vo... and treat patients with tetralogy of,Fallot (TOF)...ournal,Cardiology (2008; Vol. 101, Issue 1, 107-11...
...SOUTH SAN FRANCISCO, Calif., April 8, 2008 ,Anesiv...votal Phase 3,clinical trial evaluating Adlea(TM),...ate, in patients following total knee replacement ... initiated a multicenter, randomized,double-blind,...safety and,efficacy of a single 5 or 15 mg dose of...
Other Medicine Technology:Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 2Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 3Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement 2Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement 3Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement 4
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
Medicine Products: